Synapse - Department of Medicine

Results (39669)

Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-Cell lymphomas: Results of the MSKCC phase I/II experience

Meeting Abstract

O'Connor, O. A.; Hamlin, P. A.; Gerecitano, J.; Portlock, C. S.; Noy, A.; Moskowitz, C.; Straus, D. J.; Sarasohn, D.; Dumitrescu, O.; Pappanicholaou, J.; more...
Blood (2006)

Fulltext@MSK | Save

A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastorna multiforme (GBM)

Meeting Abstract

Nguyen, T. D.; Lassman, A. B.; Lis, E.; Rosen, N.; Shaffer, D. R.; Scher, H. I.; Deangelis, L. M.; Abrey, L. E.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

Early phase experience with pralatrexate (10-propargyl-10-deazaaminopterin [PRX]), a novel antifolate with high affinity for the reduced folate carrier, in patients with chemotherapy refractory lymphoproliferative malignancies

Meeting Abstract

O'connor, O.; Hamlin, P.; Neylon, E.; Moskowitz, C.; Portlock, C.; Noy, A.; Sirotnak, F.; Zelenetz, A.; Mould, D.; Horwitz, S.
EJC Supplements (2006)

Fulltext@MSK | Save

A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastoma multiforme (GBM)

Meeting Abstract

Nguyen, T. D.; Lassman, A. B.; Lis, E.; Rosen, N.; Shaffer, D. R.; Scher, H. I.; Deangelis, L. M.; Abrey, L. E.
Neuro-Oncology (2006)

Fulltext@MSK | Save

Can differences in bowel function after surgery for rectal cancer be identified using the European Organization for Research and Treatment of Cancer (EORTC) quality of life (QOL) instruments?

Meeting Abstract

Neuman, H. B.; Schrag, D.; Cabral, C.; Weiser, M.; Paty, P.; Guillem, J.; Minsky, B. D.; Wong, W. D.; Temple, L.
Annals of Surgical Oncology (2006)

Fulltext@MSK | Save

Quality of life (QOL) companion to CALGB 9840: A phase III study of paclitaxel (P) via weekly 1 hour (hr) versus standard 3 hour infusion every 3 weeks with trastuzumab in the treatment of patients with/without HER-2/neu-overexpressing metastatic breast cancer

Meeting Abstract

Naughton, M. J.; Gu, L.; Wang, X. F.; Seidman, A. D.; Winer, E.; Kornblith, A. B.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

Toxicity of older and younger patients (pts) treated (Rx) with intensive adjuvant chemotherapy (Cx) for node-positive (N plus ) breast cancer (BC): The CALGB experience

Meeting Abstract

Muss, H.; Berry, D.; Cirrincione, C.; Budman, D.; Henderson, I.; Citron, M.; Norton, L.; Winer, E.; Hudis, C.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

Prophylactic oophorectomy in premenopausal women with non-metastatic colon cancer: A decision analysis

Meeting Abstract

Mourton, S. M.; Hollenberg, J. P.; Abu-Rustum, N. R.; Chi, D. S.; Wong, W. D.; Temple, L. K.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-Α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Rixe, O.; Oudard, S.; Kim, S. T.; Baum, C. M.; Figlin, R. A.
Annals of Oncology (2006)

Fulltext@MSK | Save

Phase III randomized trial of sunitinib malate (SU1 1248) versus interferon-alfa (IFN-alpha) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Rixe, O.; Oudard, S.; Kim, S. T.; Baum, C. M.; Figlin, R. A.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save